newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Reuters
Rovadicitinib is an oral drug that simultaneously targets inflammation and tissue scarring.
Sino Biopharmaceutical's unit will grant Sanofi exclusive global rights for rovadicitinib.
KEY POINTS
Sanofi will pay an upfront fee of $135 million for rovadicitinib rights.
Potential milestone payments to Sino Biopharmaceutical could reach up to $1.40 billion.
Rovadicitinib targets both inflammation and tissue scarring as a dual-action oral drug.
The licence agreement requires regulatory clearances before completion.
Under the agreement, Sino Biopharmaceutical's subsidiary Chia Tai Tianqing Pharmaceutical Group will grant Sanofi an exclusive worldwide licence to develop, manufacture and commercialise rovadicitinib, receiving an upfront payment of $135 million.
Sign up here.
The company is also eligible to receive potential development, regulatory and sales milestone payments of up to $1.40 billion.
Rovadicitinib is an oral drug that simultaneously targets inflammation and tissue scarring, two hallmarks of the diseases it is designed to treat.
It belongs to a class of drugs known as JAK/ROCK inhibitors, which work by blocking enzymes that drive both processes.
The deal is subject to customary closing conditions, including regulatory clearances, Sino Biopharmaceutical said.
Reporting by Shivangi Lahiri in Bengaluru; Editing by Tasim Zahid